A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Jadamba, Erkhembayar ^a   Shin, Miyoung ^a  

^a Kyungpook National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; ALSTERPAULLONE; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CELASTROL; DOXORUBICIN; ENTINOSTAT; EXEMESTANE; FULVESTRANT; GW 8510; LETROZOLE; MEGESTROL; METHOTREXATE; PACLITAXEL; PHENOXYBENZAMINE; TAMOXIFEN; UNCLASSIFIED DRUG; VINBLASTINE; DRUG; TRANSCRIPTOME;

ARTICLE; BREAST CANCER; DRUG DETERMINATION; DRUG REPOSITIONING; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; KNOWLEDGE BASE; PHENOTYPE; PROSTATE CANCER; VALIDATION PROCESS; BREAST NEOPLASMS; DATA MINING; FEMALE; GENETICS; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; DATA MINING; DRUG REPOSITIONING; FEMALE; GENOMICS; HUMANS; PHARMACEUTICAL PREPARATIONS; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 85009423948     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/7147039     Document Type: Article

References (60)

1. T. T. Ashburn and K. B. Thor, "Drug repositioning: identifying and developing new uses for existing drugs, " Nature Reviews Drug Discovery, vol. 3, no. 8, pp. 673-683, 2004.
2. T. I. Oprea and J. Mestres, "Drug repurposing: far beyond new targets for old drugs, "The AAPS Journal, vol. 14, no. 4, pp. 759-763, 2012.
3. F. Napolitano, Y. Zhao, V. M. Moreira et al., "Drug repositioning: amachine-learning approach through data integration, " Journal of Cheminformatics, vol. 5, no. 1, pp. 1-9, 2013.
4. J. Li, S. Zheng, B. Chen, A. J. Butte, S. J. Swamidass, and Z. Lu, "A survey of current trends in computational drug repositioning, " Briefings in Bioinformatics, vol. 17, no. 1, pp. 2-12, 2016.
5. S. J. Swamidass, "Mining small-molecule screens to repurpose drugs, " Briefings in Bioinformatics, vol. 12, no. 4, pp. 327-335, 2011.
6. J. Lamb, E. D. Crawford, D. Peck et al., "The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease, " Science, vol. 313, no. 5795, pp. 1929-1935, 2006.
7. J. Lamb, "The connectivity map: a new tool for biomedical research, " Nature Reviews Cancer, vol. 7, no. 1, pp. 54-60, 2007.
8. F. Iorio, R. Tagliaferri, and D. DiBernardo, "Identifyingnetwork of drug mode of action by gene expression profiling, " Journal of Computational Biology, vol. 16, no. 2, pp. 241-251, 2009.
9. A. Subramanian, P. Tamayo, V. K. Mootha et al., "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545-15550, 2005.
10. Y. Silberberg, A. Gottlieb, M. Kupiec, E. Ruppin, and R. Sharan, "Large-scale elucidation of drug response pathways in humans, " Journal of Computational Biology, vol. 19, no. 2, pp. 163-174, 2012.
11. F. Iorio, R. Bosotti, E. Scacheri et al., "Discovery of drugmode of action and drug repositioning from transcriptional responses, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14621-14626, 2010.
12. J. A. Parkkinen and S. Kaski, "Probabilistic drug connectivity mapping, " BMC Bioinformatics, vol. 15, article 113, 2014.
13. J. Yu, P. Putcha, and J. M. Silva, "Recovering drug-induced apoptosis subnetwork from connectivity map data, " BioMed Research International, vol. 2015, Article ID 708563, 11 pages, 2015.
14. A. Pujol, R. Mosca, J. Farrés, and P. Aloy, "Unveiling the role of network and systems biology in drug discovery, " Trends in Pharmacological Sciences, vol. 31, no. 3, pp. 115-123, 2010.
15. H. Chen, H. Zhang, Z. Zhang, Y. Cao, and W. Tang, "Networkbased inference methods for drug repositioning, " Computational andMathematical Methods in Medicine, vol. 2015, Article ID 130620, 7 pages, 2015.
16. V. Law, C. Knox, Y. Djoumbou et al., "DrugBank 4. 0: shedding new light on drug metabolism, " Nucleic Acids Research, vol. 42, no. 1, pp. D1091-D1097, 2014.
17. A. Hamosh, A. F. Scott, J. S. Amberger, C. A. Bocchini, andV. A. McKusick, "Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders, " Nucleic Acids Research, vol. 33, pp. D514-D517, 2005.
18. D. Emig, A. Ivliev, O. Pustovalova et al., "Drug target prediction and repositioning using an integrated network-based approach, " PLoS ONE, vol. 8, no. 4, Article ID e60618, 2013.
19. G. H. Hu and P. Agarwal, "Human disease-drug network based on genomic expression profiles, " PLoS ONE, vol. 4, no. 8, Article ID e6536, 2009.
20. M. A. Yildirim, K.-I. Goh, M. E. Cusick, A.-L. Barabási, and M. Vidal, "Drug-target network, " Nature Biotechnology, vol. 25, no. 10, pp. 1119-1126, 2007.
21. M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, and B. K. Shoichet, "Relating protein pharmacology by ligand chemistry, " Nature Biotechnology, vol. 25, no. 2, pp. 197-206, 2007.
22. F. Tan, R. Yang, X. Xu et al., "Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity, " Molecular BioSystems, vol. 10, no. 5, pp. 1126-1138, 2014.
23. M. Kuhn, C. vonMering, M. Campillos, L. J. Jensen, and P. Bork, "STITCH: interaction networks of chemicals and proteins, " Nucleic Acids Research, vol. 36, no. 1, pp. D684-D688, 2008.
24. F. Zhu, Z. Shi, C. Qin et al., "Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery, " Nucleic Acids Research, vol. 40, no. 1, pp. D1128-D1136, 2012.
25. A. Ramasamy, A. Mondry, C. C. Holmes, and D. G. Altman, "Key issues in conducting a meta-analysis of gene expression microarray datasets, " PLoS Medicine, vol. 5, no. 9, p. e184, 2008.
26. M. Iskar, M. Campillos, M. Kuhn, L. J. Jensen, V. van Noort, and P. Bork, "Drug-induced regulation of target expression, " PLoS Computational Biology, vol. 6, no. 9, Article ID e1000925, 2010.
27. F. Napolitano, F. Sirci, D. Carrella, and D. di Bernardo, "Drugset enrichment analysis: a novel tool to investigate drug mode of action, " Bioinformatics, vol. 32, no. 2, pp. 235-241, 2016.
28. I. B. Pau Ni, Z. Zakaria, R. Muhammad et al., "Gene expression patterns distinguish breast carcinomas from normal breast tissues: theMalaysian context, " Pathology Research and Practice, vol. 206, no. 4, pp. 223-228, 2010.
29. K. Graham, A. De Las Morenas, A. Tripathi et al., "Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile, " British Journal of Cancer, vol. 102, no. 8, pp. 1284-1293, 2010.
30. Y. Wang, J. G. M. Klijn, Y. Zhanget al., "Gene-expressionprofiles to predict distant metastasis of lymph-node-negative primary breast cancer, "The Lancet, vol. 365, no. 9460, pp. 671-679, 2005.
31. C. Sotiriou, P. Wirapati, S. Loi et al., "Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis, " Journal of the National Cancer Institute, vol. 98, no. 4, pp. 262-272, 2006.
32. R. Edgar, M. Domrachev, and A. E. Lash, "Gene Expression Omnibus: NCBI gene expression and hybridization array data repository, " Nucleic Acids Research, vol. 30, no. 1, pp. 207-210, 2002.
33. R. A. Irizarry, B. Hobbs, F. Collinet al., "Exploration, normalization, and summaries of high density oligonucleotide array probe level data, " Biostatistics, vol. 4, no. 2, pp. 249-264, 2003.
34. K. A. Gray, B. Yates, R. L. Seal, M. W. Wright, andE. A. Bruford, "Genenames. org: the HGNC resources in 2015, " Nucleic Acids Research, vol. 43, no. D1, pp. D1079-D1085, 2015.
35. A. Liberzon, A. Subramanian, R. Pinchback, H. Thorvaldsdóttir, P. Tamayo, and J. P. Mesirov, "Molecular signatures database (MSigDB) 3. 0, " Bioinformatics, vol. 27, no. 12, pp. 1739-1740, 2011.
36. M. Kanehisa, M. Araki, S. Goto et al., "KEGG for linking genomes to life and the environment, " Nucleic Acids Research, vol. 36, no. 1, pp. D480-D484, 2008.
37. L. Matthews, G. Gopinath, M. Gillespie et al., "Reactome knowledgebase of human biological pathways and processes, " Nucleic Acids Research, vol. 37, no. 1, pp. D619-D622, 2009.
38. D. Szklarczyk, A. Franceschini, S. Wyder et al., "STRING v10: protein-protein interaction networks, integrated over the tree of life, " Nucleic Acids Research, vol. 43, no. 1, pp. D447-D452, 2015.
39. M. Kuhn, D. Szklarczyk, S. Pletscher-Frankild et al., "STITCH 4: integration of protein-chemical interactions with user data, " Nucleic Acids Research, vol. 42, no. D1, pp. D401-D407, 2014.
40. H. Jandu, K. Aluzaite, L. Fogh et al., "Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines, " BMC Cancer, vol. 16, no. 1, article 34, 2016.
41. H.-J. Kim, S.-A. Im, B. Keam et al., "ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy, " Cancer Science, vol. 106, no. 1, pp. 86-93, 2015.
42. E. Devarajan, A. A. Sahin, J. S. Chen et al., "Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance, " Oncogene, vol. 21, no. 57, pp. 8843-8851, 2002.
43. B. M. Müller, L. Jana, A. Kasajima et al., "Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression, " BMC Cancer, vol. 13, no. 1, article 215, pp. 1-8, 2013.
44. E. A. Musgrove, C. E. Caldon, J. Barraclough, A. Stone, and R. L. Sutherland, "Cyclin D as a therapeutic target in cancer, " Nature Reviews Cancer, vol. 11, no. 8, pp. 558-572, 2011.
45. S. Nidhyanandan, T. S. Boreddy, K. B. Chandrasekhar, N. D. Reddy, N. M. Kulkarni, and S. Narayanan, "Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo, " European Journal of Pharmacology, vol. 764, pp. 508-519, 2015.
46. R. K. Srivastava, R. Kurzrock, and S. Shankar, "MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo, "Molecular CancerTherapeutics, vol. 9, no. 12, pp. 3254-3266, 2010.
47. T. R. Singh, S. Shankar, and R. K. Srivastava, "HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma, " Oncogene, vol. 24, no. 29, pp. 4609-4623, 2005.
48. Y. Y. Hsieh, C. J. Chou, H. L. Lo, and P. M. Yang, "Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductaseM2 inhibitor to treat human colorectal cancer, " Cell Death Discovery, vol. 2, Article ID16027, 2016.
49. F.-H. Chung, Y.-R. Chiang, A.-L. Tseng et al., "Functional Module ConnectivityMap (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma, " PLoS ONE, vol. 9, no. 1, Article ID e86299, 2014.
50. R. A. Shamanna, H. Lu, D. L. Croteau et al., "Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer, " Oncotarget, vol. 7, no. 12, pp. 13269-13284, 2016.
51. S. J. Conley, T. L. Baker, J. P. Burnett et al., "CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer, " Breast Cancer Research and Treatment, vol. 150, no. 3, pp. 559-567, 2015.
52. J. T. Sims, S. Ganguly, L. S. Fiore, C. J. Holler, E.-S. Park, and R. Plattner, "STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner, " Biochemical Pharmacology, vol. 78, no. 3, pp. 249-260, 2009.
53. A. Fujimori, M. Gupta, Y. Hoki, and Y. Pommier, "Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair, " Molecular Pharmacology, vol. 50, no. 6, pp. 1472-1478, 1996.
54. L. G. Sheffield, "C-Src activation by ErbB2 leads to attachmentindependent growth of human breast epithelial cells, " Biochemical and Biophysical Research Communications, vol. 250, no. 1, pp. 27-31, 1998.
55. D. Kedrin, J. Wyckoff, P. J. Boimel et al., "ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation, " Clinical Cancer Research, vol. 15, no. 11, pp. 3733-3739, 2009.
56. Sigma-Aldrich, Tyrphostin AG 825: Highlights of Prescribing Information, Sigma-Aldrich, 2016.
57. C. C. Faria, S. Agnihotri, S. C. Mack et al., "Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma, " Oncotarget, vol. 6, no. 25, pp. 21718-21729, 2015.
58. J.-I. Chao, W.-C. Su, and H.-F. Liu, "Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT, " Molecular Cancer Therapeutics, vol. 6, no. 11, pp. 3039-3048, 2007.
59. S. Shrivastava, M. K. Jeengar, V. S. Reddy, G. B. Reddy, and V. G. M. Naidu, "Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways, " Experimental and Molecular Pathology, vol. 98, no. 3, pp. 313-327, 2015.
60. C. Mi, H. Shi, J. Ma, L. Z. Han, J. J. Lee, and X. Jin, "Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9, " Oncology Reports, vol. 32, no. 6, pp. 2527-2532, 2014.